• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 3. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 4. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 5. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines N-acylpyrrolidines

Recent Advances in the Study of 2-Pyrrolidinecarbonitrile, 1-(chloroacetyl)-4-fluoro-, (2S,4S)- (CAS: 596817-06-0)

The compound 2-Pyrrolidinecarbonitrile, 1-(chloroacetyl)-4-fluoro-, (2S,4S)- (CAS: 596817-06-0) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. This chiral pyrrolidine derivative is particularly notable for its role as a key intermediate in the synthesis of bioactive molecules, including protease inhibitors and other therapeutic agents. Recent studies have focused on its stereoselective synthesis, pharmacological properties, and utility in the design of novel drug candidates.

A 2023 study published in the Journal of Medicinal Chemistry highlighted the efficient asymmetric synthesis of (2S,4S)-2-Pyrrolidinecarbonitrile derivatives, including 596817-06-0, using a catalytic enantioselective approach. The researchers employed a chiral palladium catalyst to achieve high enantiomeric excess (ee > 99%) and yield (85%), demonstrating the compound's suitability for scalable production. The study also explored its reactivity in subsequent transformations, such as nucleophilic substitutions, to generate diverse pharmacophores.

In another recent investigation, the compound's role as a building block for dipeptidyl peptidase-4 (DPP-4) inhibitors was elucidated. DPP-4 inhibitors are a class of antidiabetic drugs, and the (2S,4S)-stereochemistry of 596817-06-0 was found to be critical for binding affinity and selectivity. Molecular docking studies revealed that the fluoro and chloroacetyl groups enhance interactions with the enzyme's active site, suggesting potential for further optimization in drug design.

Furthermore, a 2024 preprint on bioRxiv reported the use of 2-Pyrrolidinecarbonitrile, 1-(chloroacetyl)-4-fluoro-, (2S,4S)- in the development of covalent inhibitors targeting SARS-CoV-2 main protease (M^pro). The chloroacetyl moiety was leveraged to form a covalent bond with the catalytic cysteine residue, yielding potent inhibitors with nanomolar IC₅₀ values. This study underscores the compound's versatility in addressing emerging infectious diseases.

Despite these advancements, challenges remain in optimizing the pharmacokinetic properties of derivatives derived from 596817-06-0. A recent review in ACS Chemical Biology emphasized the need for further in vivo studies to assess metabolic stability and toxicity. Nevertheless, the compound's unique structural features and synthetic accessibility position it as a promising scaffold for future therapeutic development.

In conclusion, 2-Pyrrolidinecarbonitrile, 1-(chloroacetyl)-4-fluoro-, (2S,4S)- (CAS: 596817-06-0) continues to be a focal point in medicinal chemistry research. Its applications span from diabetes treatment to antiviral therapy, driven by its stereochemical precision and functional group diversity. Ongoing studies are expected to unlock its full potential in drug discovery pipelines.

• 676561-06-1(2-Pyrrolidinecarbonitrile, 1-(chloroacetyl)-5-methyl-, (2S,5S)- (9CI))
• 651056-43-8(2-Pyrrolidinecarbonitrile, 1-(chloroacetyl)-4-fluoro-, (2R,4R)-)
• 651056-39-2(2-Pyrrolidinecarbonitrile, 1-(chloroacetyl)-4-fluoro-, (2S,4R)-)
• 651056-41-6(2-Pyrrolidinecarbonitrile, 1-(chloroacetyl)-4-fluoro-, (2R,4S)-)
• 866396-78-3(2,5-Pyrrolidinedicarbonitrile, 1-(chloroacetyl)-, (2R,5S)-rel-)
• 596817-02-6( )
• 207557-35-5((2S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile)
• 949153-15-5(DBPR108 Impurity 8)
• 565452-98-4((2R)-1-(Chloroacetyl)-2-pyrrolidinecarbonitrile)
• 274901-37-0(2-Pyrrolidinecarbonitrile, 1-(chloroacetyl)-)